Steven R. Goldstein, M.D., Joins Bionovo's Menerba Medical Advisory Board

EMERYVILLE, Calif., Nov. 5 /PRNewswire-FirstCall/ --Bionovo, Inc. (Nasdaq:
BNVI) announced today the appointment of Steven R. Goldstein, M.D., to the
company's Medical Advisory Board. Dr. Goldstein is a world leader on uterine
safety. He has extensive experience in menopausal and perimenopausal uterine
safety studies for several Selective Estrogen Receptor Modulators (SERMS).

"We are very excited to have Dr. Goldstein on the medical advisory board as we
are advancing Menerba(TM) to Phase 3," said Mary Tagliaferri, M.D., L.Ac.,
Bionovo's President and Chief Medical Officer. She added, "Given the concern
from the FDA regarding uterine safety in postmenopausal trials using
traditional estrogen therapy, his groundbreaking work and expertise in
menopausal ultrasounds will be highly pertinent during the Menerba Phase 3
trial."

Dr. Goldstein states, "I look forward to working with Bionovo on the
development of their novel estrogen receptor beta agonist drug, Menerba, for
the treatment of postmenopausal vasomotor symptoms. Current estrogen
treatments are associated with a 12 to 24 fold increase in uterine cancer;
therefore alternative therapies are desperately needed for the treatment of
hot flashes in postmenopausal women."

Dr. Steven Goldstein is the current Director of Gynecologic Ultrasound at New
York University Medical Center; he is the current 1st Vice President of the
American Institute of Ultrasound in Medicine. He has authored many textbooks
including: "Endovaginal Ultrasound", "Ultrasound in Gynecology" and "Textbook
in Perimenopausal Gynecology". Additionally, he has authored more than a dozen
textbook chapters as well as over 55 original research articles. He has been a
guest faculty member, invited speaker, visiting professor or course director
over 295 times in the United States and worldwide. He currently has authored
two recently released books: "Could it Be... Perimenopause" and "The Estrogen
Alternative." He is one of the most highly recognized and regarded individuals
in the field of vaginal ultrasound.

Dr. Goldstein graduated Magna Cum Laude from Colgate University with a
Baccalaureate degree in Biology. He graduated from the New York University
School of Medicine in 1975 and completed his internship in Obstetrics and
Gynecology at Parkland Memorial Hospital in Dallas, Texas from 1975-1976. He
completed his residency in Obstetrics and Gynecology at New York University
Affiliated Hospital/Bellevue Hospital Center from 1976-1980. He has been
serving as clinical instructor at New York University School of Medicine since
1980 and full tenured Professor of Obstetrics and Gynecology since 1996.

Menerba

Menerba is an estrogen receptor (ER) beta selective drug developed as an
alternative to postmenopausal hormone products currently on the market, which
are both ER beta and ER alpha agonists that have been shown to increase the
risk for breast and uterine cancers. It has been shown that the increased risk
of breast and uterine cancers is associated with ER alpha activation and that
ER beta blocks the growth promoting effects on breast cancer cells. Bionovo
recognized the opportunity to commercialize a product that would be equally
effective, with an improved safety profile compared to traditional hormone
therapy. The clinical trial results have been evaluated by an independent Data
and Safety Monitoring Board and the drug candidate has passed through a
standard two-phase examination for safety.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development
of safe and effective treatments for women's health and cancer, markets with
significant unmet needs and billions in potential annual revenue. The company
applies its expertise in the biology of menopause and cancer to design new
drugs derived from botanical sources which have novel mechanisms of action.
Based on the results of early and mid-stage clinical trials, Bionovo believes
they have discovered new classes of drug candidates within their rich pipeline
with the potential to be leaders in their markets. Bionovo is headquartered in
Emeryville, California and is traded on the NASDAQ Capital Market under the
symbol, "BNVI". For more information about Bionovo and its programs, visit
http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the
business of Bionovo, Inc. that can be identified by the use of forward-looking
terminology such as "believes," "expects," or similar expressions. Such
forward-looking statements involve known and unknown risks and uncertainties,
including uncertainties relating to product development, efficacy and safety,
regulatory actions or delays, the ability to obtain or maintain patent or
other proprietary intellectual property protection, market acceptance,
physician acceptance, third party reimbursement, future capital requirements,
competition in general and other factors that may cause actual results to be
materially different from those described herein as anticipated, believed,
estimated or expected. Certain of these risks and uncertainties are or will be
described in greater detail in our filings with the Securities and Exchange
Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under
no obligation (and expressly disclaims any such obligation) to update or alter
its forward-looking statements whether as a result of new information, future
events or otherwise.

SOURCE Bionovo, Inc.

Tom Chesterman of Bionovo, Inc., +1-510-601-2000, investor@bionovo.com; or
Investors, Joe Diaz, Robert Blum or Joe Dorame, all of Lytham Partners, LLC,
+1-602-889-9700, bnvi@lythampartners.com, for Bionovo, Inc.